Aclarion announced that Roger Hartl, M.D., Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, as well as the co-director of New York-Presbyterian Och Spine, will advise the company as a key opinion leader nationally. Over the past 18 months, Aclarion has built a leading consortium of 10 KOL surgeons. Dr. Hartl represents the 10th and final KOL addition to Aclarion’s panel. The Company is now in the critical stage of activating MRIs for each of its KOLs so they can begin using the technology, tracking clinical results, and advocating for payer coverage decisions to expand access to Nociscan to all patients. The Company will announce additional MRI activations for the remaining KOLs as they become available and will begin to report on scan volumes as Nociscan use grows with these MRI activations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACON:
- Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver
- Aclarion announces signing of commercial agreement with Porter Hospital
- Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting
- Aclarion presents poster on Nosciscan cost-effectiveness
- Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan